Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $3.06 billion. The enterprise value is $2.76 billion.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 63.32 million shares outstanding. The number of shares has increased by 33.07% in one year.
| Current Share Class | 63.32M |
| Shares Outstanding | 63.32M |
| Shares Change (YoY) | +33.07% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 80.40% |
| Float | 51.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.20 |
| P/TBV Ratio | 10.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.76, with a Debt / Equity ratio of 0.19.
| Current Ratio | 13.76 |
| Quick Ratio | 13.43 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.33 |
Financial Efficiency
Return on equity (ROE) is -65.11% and return on invested capital (ROIC) is -36.53%.
| Return on Equity (ROE) | -65.11% |
| Return on Assets (ROA) | -33.37% |
| Return on Capital (ROIC) | -36.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.63M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +257.06% in the last 52 weeks. The beta is 1.02, so VERA's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +257.06% |
| 50-Day Moving Average | 43.47 |
| 200-Day Moving Average | 40.72 |
| Relative Strength Index (RSI) | 59.07 |
| Average Volume (20 Days) | 1,158,049 |
Short Selling Information
The latest short interest is 6.39 million, so 10.09% of the outstanding shares have been sold short.
| Short Interest | 6.39M |
| Short Previous Month | 6.19M |
| Short % of Shares Out | 10.09% |
| Short % of Float | 12.41% |
| Short Ratio (days to cover) | 7.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -145.28M |
| Pretax Income | -107.85M |
| Net Income | -134.38M |
| EBITDA | n/a |
| EBIT | -145.28M |
| Earnings Per Share (EPS) | -$2.62 |
Full Income StatementBalance Sheet
The company has $353.31 million in cash and $54.91 million in debt, giving a net cash position of $298.40 million or $4.71 per share.
| Cash & Cash Equivalents | 353.31M |
| Total Debt | 54.91M |
| Net Cash | 298.40M |
| Net Cash Per Share | $4.71 |
| Equity (Book Value) | 289.06M |
| Book Value Per Share | 5.25 |
| Working Capital | 337.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$120.64 million and capital expenditures -$390,000, giving a free cash flow of -$121.03 million.
| Operating Cash Flow | -120.64M |
| Capital Expenditures | -390,000 |
| Free Cash Flow | -121.03M |
| FCF Per Share | -$1.91 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |